

Effect Of Vitamin D Status and Serum Ferritin Concentration On
Early Virological Response Of Chronic Hepatitis C Virus To
Standard Care Therapy

Thesis by
Eman Soliman Mohamed
M.B. B. Ch
Faculty of medicine
Ain shams university

For partial fulfillment of
Master degree in internal medicine

Under supervision of

Prof Dr. Ahmed Shawki El-Sawaby
Professor of internal medicine and gastroenterology
Faculty of medicine- Ain Shams University

Dr. Amir Helmy Samy
Assistant Prof of internal medicine and gastroenterology
Faculty of medicine- Ain Shams University

Dr .Khaled Amr Zaki
Lecturer of internal medicine and gastroenterology
Faculty of medicine- Ain Shams Universit

Department of internal medicine
Faculty of medicine
Ain Shams University
2015

تأثير حالة فيتامين د و تركيز الفريتين بالمصل علي الاستجابة
الفيروسية المبكرة للإصابة بالالتهاب الكبدي الفيروسي المزمن سي
للعلاج و الرعاية القياسية

رسالة

توطئة للحصول علي درجة الماجستير

في أمراض الباطنة العامة

مقدمة من

الطبيبة / إيمان سليمان محمد

تحت إشراف

أ.د/ أحمد شوقي الصوابي

أستاذ الباطنة العامة و الجهاز الهضمي والكبد

كلية الطب - جامعة عين شمس

أ.د/ أمي حلمي سامي

أستاذ م الباطنة العامة و الجهاز الهضمي والكبد

كلية الطب - جامعة عين شمس

د/ خالد عمرو زلثي

مدرس الباطنة العامة و الجهاز الهضمي والكبد

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

2015



قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم
سورة البقرة الآية (٣٢)

ACKNOWLEDGEMENTS

CONTENTS

Content	Page
· Introduction.....	1
· Aim of the Work.....	7
· Review of Literature	
Chapter 1: Hepatitis C Virus.....	8
Chapter 2: Management of HCV Infection.....	24
Chapter 3: vitamin D level in chronic hepatitis c.....	89
Chapter 4: serum iron and ferritin in chronic hepatitis c.....	99
· Patients and methods.....	110
· Results	119
· Discussion.....	139
· Summary	151
· conclusion	153
· References.....	154
· Arabic summary	

LIST OF Figures

Figure No.	Title	Page
1-	Hepatitis C virus in Egypt compared to other countries in the world...	11
2-	Natural history of HCV infection	13
3-	The Hepatitis C Virus (HCV) Lifecycle	15
4-	Pathology of cryoglobulinemia.....	33
5-	Skin lesion in cryoglobulinemia.....	34
6-	Pathogenesis of hepatitis C virus-related lymphoproliferative disorders.....	36
7-	Porphyria Cutanea Tarda.....	38
8-	Oral and skin LP.....	38
9-	Mechanism of interferon action.....	54
10-	Chemical structure of ribavirin.....	57
11-	Response to interferon and ribavirin.....	78
12-	Vitamin D metabolism.....	90
13-	Percentage of responders and non-responders at 12 weeks.....	124
14-	Mean of vitamin D at different treatment stages.....	126
15-	Maen of serum ferritin at different treatment stages.....	126
16-	Spearman's linear correlation between serum ferritin and BMI in EVR group	130
17-	Spearman's linear correlation between (25-OH) vitamin D and T.bil in EVR group.....	131
18-	Spearman's linear correlation between (25-OH) vitamin D and PCRweek 12 in EVR group.....	132

Cont. Of LIST OF Figures

Figure No.	Title	Page
19-	Spearman's linear correlation between (25-OH) vitamin D and Hb level week 12.....	133
20-	ROC curve of week 0 serum ferritin for predicting EVR.....	134
21-	ROC curve of week 0 (25-OH) vitamin D for predicting EVR.....	135
22-	Comparison of AUC of ROC analysis of week 0 serum ferritin and (25-OH) vitamin D for prediction of EVR.....	136
23-	Comparison of AUC of ROC analysis of week 4 serum ferritin and (25-OH) vitamin D for prediction of EVR.....	137
24-	Comparison of AUC of ROC analysis of week 12 serum ferritin and (25-OH) vitamin D for prediction of EVR.....	138

LIST OF Tables

Table No.	Title	Page
1-	Risk Factors for Developing Chronic HCV Infection	25
2-	EHM Classification of HCV.....	30
3-	FACTORS ASSOCIATED WITH PROGRESSION OF CHRONIC HEPATITIS	43
4-	FDA Approved Qualitative Assays for Detection of HCV RNA.....	46
5-	Interpretation of HCV Assays.....	48
6-	Virological Responses during Therapy and Definitions.....	52
7-	Sources of vitamin D.....	92
8-	Description of laboratory data of the patients at different weeks of treatment.....	123
9-	Comparison between EVR and non EVR at 12 weeks as regard different parameters.....	125
10-	Regression analysis of different variables to study independent factor associated with EVR	127
11-	Comparison between vitamin D levels at week 0, 4 and 12 weeks.....	127
12-	Comparison between ferritin levels at week 0, 4 and 12 weeks.....	128
13-	Correlation between serum ferritin and Vitamin D at different weeks of treatment with different parameters.....	129
14-	Using of receiver operating characteristic (ROC) curve for (25-OH) vitamin D and serum in different weeks of treatment in prediction of EVR.....	134

Cont of.LIST OF Tables

Table No.	Title	Page
15-	Comparison ofAUC of ROC analysis of (25-OH) vitamin D and ferritin in different weeks of treatment for evaluation of diagnostic performance accuracy in prediction of EVR	136

Thanks **ALLAH** for giving me strength and patience to fulfill
this job

May You (**ALLAH**) accept it from me and consider it good and
useful

To my lovely parents and husband, thank you for your constant
inspiration and support, I couldn't have done this without
you.....

To all who will read this one day and find it useful,

Thank you for your time and trust....

Acknowledgment

*Very special thanks to **Prof.Dr., Ahmed Shawki ELSawaby**, Professor of internal medicine and gastroenterology Faculty of medicine- Ain Shams University for his constant effort and advice which extended from the time of choosing the topic and through the whole period of the practical part, writing and revision. I really learned a lot from you.*

*I am also deeply grateful **Dr. Amir Helmy Samy** Assistant Prof of internal medicine and gastroenterology Faculty of medicine- Ain Shams University for his kindness, encouragement, valuable assistance and accurate revision.*

*Special thanks to **Dr .Khaled Amr Zaki** Lecturer of internal medicine and gastroenterology Faculty of medicine- Ain Shams University.*

INTRODUCTION

Hepatitis C is caused by RNA flavivirus. Acute symptomatic infection with hepatitis C is rare, most individuals will be unaware of when they became infected and are only identified when they develop chronic liver disease. (Shiffman et al., 2003)

Hepatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver disease. (Williams 2006)

An estimated 180 million people are infected worldwide, the prevalence of HCV infection between the years 1999 and 2002 was 1.6%, equating to about 4.1 million persons positive for antibody to hepatitis C (anti-HCV), 80% of who are estimated to be viremic. (Armstrong et al., 2006)

Hepatitis C is the principal cause of death from liver disease and the leading indication for liver transplantation. (Kim, 2002)

Some calculations suggest that mortality related to HCV infection (death from liver failure or hepatocellular carcinoma) will continue to increase over the next two decades. (Deuffic et al., 2007)

The optimal approach to detecting HCV infection is to screen persons for a history of risk of exposure to the

virus, and to test selected individuals who have an identifiable risk factor. (Alter et al., 2004)

Currently, injection drug use is the primary mode of HCV transmission. Thus, all persons who use or have used illicit injection drugs in the present or in the past, even if only once, as well as intranasal drug users who share paraphernalia, should be tested for HCV infection. (Armstrong et al., 2006)

Individuals who have received a blood or blood component transfusion or an organ transplant before 1992 should also be tested. (Petta et al., 2010)

With the introduction of sensitive tests to screen blood donors for HCV antibodies in 1992, transfusion-transmission of HCV has become rare. (Wasley et al., 2005).

Persons with hemophilia should be tested for HCV infection if blood products were received before 1987, after which time, viral inactivation procedures were implemented. (Goedert et al., 2007)

Similarly, individuals with unexplained elevations of the aminotransferase levels (alanine and/or aspartate aminotransferase; ALT/AST), those ever on hemodialysis, children born to HCV-infected mothers, or those with human immunodeficiency virus (HIV)

infection should be tested for the presence of HCV infection. (Mast et al., 2005)

Other potential sources of HCV transmission include exposure to an infected sexual partner or multiple sexual partners; exposure among health care workers to HCV contaminated blood and blood products, and tattooing. (Workowski and Berman 2006)

This is a list of persons who should be routinely screened for HCV infection. For some groups, such as those with a history of injection drug use or persons with hemophilia, the prevalence of HCV is high (90%). For other groups (recipients of blood transfusions prior to 1992), the prevalence is moderate (10%). For still others, (persons with needle stick exposure, sexual partners of HCV-infected persons), the prevalence is low (1% to 5%).

Persons for Whom HCV Screening is Recommended:

- Persons who have injected illicit drugs in the recent and remote past, including those who injected only once and don't consider themselves to be drug users.
- Persons with hemophilia who received clotting factor concentrate prior to 1987.
- Persons with HIV.

-
- Persons who ever been on hemodialysis .
 - Persons with unexplained abnormal aminotransferase levels.
 - Persons who received a transfusion of blood or blood products.
 - Children born to HCV -infected mothers.
 - Health care, emergency medical and public safety workers after a needle stick injury or mucosal exposure to HCV- positive blood.
 - Persons who received organ transplantation. (conte et al.,2009)

Chronic hepatitis C affects 170 million people worldwide and is a major cause of chronic liver disease. Combination therapy with pegylated interferon (PEG-IFN) alpha and ribavirin is the current standard of care, but it has limited efficacy and a high cost. During the last decade, several modifiable and non-modifiable parameters have been identified to help clinicians predict the probability of achieving a sustained viral response (SVR) prior to treatment in individual patients. (Iambrecht et al., 2011)

Two new predictors of response to antiviral treatment have emerged:

1- Serum ferritin concentration:

HCV interferes with the host's iron metabolism, and hepatic iron measures were correlated with the grade and stage, as well as with the treatment outcome, of CHC. (Bonkovsky et al., 2006)

Infection with HCV leads to iron accumulation in the liver and increased serum ferritin levels, which can be, at least partially, explained by down-regulation of hepcidin, a key regulator of iron homeostasis. (Nishina et al., 2008)

However, serum ferritin is also frequently elevated in inflammatory conditions. Excess iron in the liver promotes liver inflammation, oxidative stress, and mitochondrial dysfunction. (Drakesmith and Prentice 2008)

2- Serum vitamin D concentration:

Is also of great interest because it is easily modifiable by dietary supplementation. Based on several recent reports demonstrating that vitamin D appears to possess important immunomediated and antiproliferative effects. (Petta et al., 2010)